News

NEW BREAKTHROUGH TEST DETECTS AND PREDICTS SEVERITY OF COVID-19

CHARLOTTESVILLE, Va., /PRNewswire/ — AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. The company’s new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.

AMPEL’s new genomic test, known as CovGENE®, has been validated by a longitudinal study in partnership with physicians in the Division of Pulmonary and Critical Care Medicine of the University of Virginia Medical Center. With careful analysis of patients admitted to the UVA Intensive Care Unit, CovGENE® demonstrated remarkable precision with a greater than 90-percent rate of accuracy. CovGENE®, can be administered by drawing a patient’s blood to quickly ascertain whether a Covid-19 patient will have a mild, moderate, or severe outcome. The findings are detailed in a paper published today by Frontiers in Immunology.

“This unique collaboration with our colleagues from the University of Virginia has provided an easy and novel means to assess an individual patient’s response to the SARS-CoV-2 virus and predict the clinical outcome,” said Dr. Peter Lipsky, AMPEL Chief Medical Officer, CEO and co-founder. “Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with Covid-19 and reduce the number of hospitalizations, especially the most vulnerable.”

AMPEL is currently working to secure a partnership with a diagnostic testing company to make CovGENE® available to the general public at a crucial time as different variants continue to emerge across the globe and with winter around the corner, when major spikes can occur. CovGENE® also holds promise in predicting long COVID, an elusive diagnosis the medical community is still trying to fully understand.

“We have come far in the prevention and treatment of COVID-19 in the past 2 years. Regardless, we still struggle to identify patients at highest risk for severe disease. Our study uses a gene analysis approach to identify an immune cell signature, distinct from other respiratory illnesses that correlates with worse outcome,” said Dr. Alexandra Kadl, lead author from the University of Virginia Division of Pulmonary and Critical Care Medicine. “This knowledge will help evaluate patients’ immune profile with commonly, readily available assays to identify patients at risk for bad outcome that would benefit from closer monitoring and advanced therapies to aid their recovery.”

AMPEL has become a bio-industry leader in precision medicine by utilizing a data driven and machine learning approach to positively impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatments more precisely.  AMPEL’s co-founders Dr. Amrie Grammer and Dr. Peter Lipsky, are internationally known for their work in genomics, and were also recent panelists at the Precision Medicine World Conference.

Read more here.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights